Join to View Full Profile
200 West Arbor Dr Mc 0949Ucsd Medical CenterSan Diego, CA 92103
Phone+1 858-622-2028
Dr. Aisen is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Case Western Reserve University/University Hospitals Cleveland Medical CenterResidency, Internal Medicine, 1979 - 1982
Columbia University Vagelos College of Physicians and SurgeonsClass of 1979, MD
Certifications & Licensure
CA State Medical License 2008 - 2027
DC State Medical License 1999 - 2010
VA State Medical License 1999 - 2002
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Rheumatology
Publications & Presentations
PubMed
- 2 citationsAmyloid PET in Sporadic Early- Versus Late-Onset Alzheimer's Disease: Comparison of the LEADS and ADNI Cohorts.Julien Lagarde, Piyush Maiti, Daniel R Schonhaut, Ganna Blazhenets, Jiaxiuxiu Zhang
Annals of Neurology. 2025-08-01 - Advancing the science of recruitment for Alzheimer's clinical trials: Challenges and opportunities.Paul Aisen, Desi Peneva, Maria-Alice Manetas, Mireille Jacobson, Dana Goldman
The Journal of Prevention of Alzheimer's Disease... 2025-08-01 - 1 citationsChanges in Daily Functioning in Association With Tau and Amyloid Among Unimpaired Older Adults With and Without Elevated Amyloid.Mark A Dubbelman, Andy Liu, Michael C Donohue, Oliver Langford, Rema Raman
Neurology. 2025-06-24
Press Mentions
University of Maryland School of Medicine Launches Groundbreaking Study on THC/CBD Therapy for Dementia-Related Agitation at End of LifeJuly 10th, 2025- Will Alzheimer’s Disease Become Preventable Within a Decade? Researchers from USC ATRI Say ‘Yes’June 20th, 2025
- Small Study Hints Anti-Amyloid Therapy May Keep Alzheimer’s Symptoms at Bay in Certain PatientsMarch 21st, 2025
Grant Support
- The Ante-Amyloid Treatment of Alzheimer's disease (A3) Trial and Alzheimer Plasma EXtension (APEX) StudyBRIGHAM AND WOMEN'S HOSPITAL2025–2030
- Life’s end Benefits of CannaBidiol and TetrahYdrocannabinol (LiBBY) Open-Label Extension (OLE) StudyMEDICAL UNIVERSITY OF SOUTH CAROLINA2025–2028
- Alzheimer's Clinical Trials Consortium (ACTC)UNIVERSITY OF SOUTHERN CALIFORNIA2017–2028
- Alzheimer's Clinical Trials Consortium (ACTC)UNIVERSITY OF SOUTHERN CALIFORNIA2017–2028
- Randomized Double Blind, Placebo Controlled, Parallel Group Trial to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease over 18 MonthsCOGNITION THERAPEUTICS, INC.2020–2027
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
